Skip to main content

Advertisement

SpringerLink
Log in

Progressive multifocal leukoencephalopathy in multiple myeloma. A literature review and lessons to learn

  • Review Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Progressive multifocal leukoencephalopathy (PML) is a rare opportunistic infection with high mortality rate usually seen in the context of immunosuppression. Although cases have been reported largely in patients with HIV/AIDS, following the use of monoclonal antibodies and occasionally in haematological malignancies, there is no review to date of patients with smouldering or treated myeloma who developed PML. Here, we conducted a literature search of PML cases in patients with multiple myeloma (MM), analyse patient and disease characteristics and describe the possible mechanisms that could lead to the development of PML. The lack of data and case reports until 2010 may indicate that PML in MM is underdiagnosed. Simultaneously, with an expanding field of new therapeutic options, patients with MM live longer, albeit continually immunosuppressed, and at risk of opportunistic infections. Emerging new treatments for PML in the horizon render the need to look out for this complication mandatory, and more case reports are needed to enrich our knowledge in this field.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Tan CS, Koralnik IJ (2010) Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 9(4):425–437

    CAS  PubMed  PubMed Central  Google Scholar 

  2. Berger JR, Aksamit AJ, Clifford DB, Davis L, Koralnik IJ, Sejvar JJ, Bartt R, Major EO, Nath A (2013) PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology 80(15):1430–1438

    PubMed  PubMed Central  Google Scholar 

  3. Akiyama M, Takahashi T, Nomura S, Yamashita Y, Hatao K (2010) Progressive multifocal leukoencephalopathy in a patient with multiple myeloma. Int J Hematol 92(1):186–189

    PubMed  Google Scholar 

  4. Troppmann M, Büttner R, Boewer M, Salzberger B (2012) Smoldering myeloma presenting as progressive multifocal leukoencephalopathy: a case report. J Med Case Rep 6:177

    PubMed  PubMed Central  Google Scholar 

  5. Hughes L, Butler A, Fink J (2010) Progressive multifocal leukoencephalopathy in a patient with multiple myeloma. Internal Medicine Journal. Conference: World Congress of Internal Medicine, WCIM 2010 in Conjunction with Physicians Week. Melbourne, VIC Australia. Conference Publication: (var.pagings). 40 (SUPPL. 1) (pp 104)

  6. Mungunkhuyag M, Harada M, Abe T, Fujita K, Matsui N, Kaji R (2014) Longitudinal monitoring with multiple MR techniques in a case of progressive multifocal leukoencephalopathy associated with multiple myeloma. Magn Reson Med Sci 13(1):55–59

    CAS  PubMed  Google Scholar 

  7. Ruiz-Heredia Y, Sanchez-Vega B, Barrio S, Linares M, Rapado I, Braggio E, Stewart K, Folgueira MD, Ramos A, Collado L, Ruiz J, Toldos O, Hernandez-Lain A, Martinez-Lopez J (2019) Concurrent progressive multifocal leukoencephalopathy and central nervous system infiltration by multiple myeloma: a case report. J Oncol Pharm Pract 25(4):998–1002

    PubMed  Google Scholar 

  8. Brigo F, Pagani E, Tezzon F, Masi E, Nardone R (2017) Lenalidomide-associated progressive multifocal leukoencephalopathy. Leuk Lymphoma 58(10):2514–2515

    PubMed  Google Scholar 

  9. Fianchi L, Colosimo C, De Luca A, Pompucci A, Cattani P, Voso MT, LaRocca LM, Leone G, Pagano L (2010) Atypical presentation of progressive multifocal leukoencephalopathy in a multiple myeloma patient after auto-SCT successfully treated with combination therapy. Bone Marrow Transplant 45(11):1668–1670

    CAS  PubMed  Google Scholar 

  10. Ripellino P, Comi C, Mula M, Varrasi C, Conconi A, Stecco A, Brustia D, Nasuelli N, Savio K, De Paoli L, Cantello R, Gaidano G, Monaco F (2011) Progressive multifocal leucoencephalopathy after autologous bone marrow transplantation: a treatment option. BMJ Case Rep bcr1120103549. https://doi.org/10.1136/bcr.11.2010.3549

  11. Yokokawa K, Hisahara S, Matsuura Y, Ikeda K, Tsuda E, Saitoh M, Nakamichi K, Saijo M, Kamihara Y, Sato T, Kawamata J, Shimohama S (2016) Progressive multifocal leukoencephalopathy after autologous peripheral blood stem cell transplantation in a patient with multiple myeloma treated with combination therapy. J Neurol Sci 368:304–306

    PubMed  Google Scholar 

  12. Sawicki CP, Climans SA, Hsia CC, Fraser JA (2018) Progressive multifocal leukoencephalopathy during ixazomib-based chemotherapy. Curr Oncol (Toronto, Ont.) 25(1):e99–e102

    CAS  Google Scholar 

  13. Bennett KM, Storrar N, Johnson P, Fernandes PM (2020) Progressive multifocal leukoencephalopathy (PML) following autologous peripheral blood stem cell transplantation for multiple myeloma. Clin Case Rep 00:1–6

    Google Scholar 

  14. Monge J, Contreras J, Elsoukkary S, Guo J, Perry A, Solomon SR, Flicker K, Jayabalan DS, Coleman M, Rossi AC, Harris R, Plate M, Stuebgen JR, Niesvizky R (2019) Progressive multifocal leukoencephalopathy in a patient with multiple myeloma receiving daratumumab and pomalidomide. Blood 134(Supplement_1):4876

    Google Scholar 

  15. Aydin Y, Salihoglu A, Uygunoglu U, Keskin D, Yurttas NO, Ozmen D, Ercaliskan A, Elverdi T, Eskazan AE, Ar MC, Ongoren S, Baslar Z, Soysal T (2019) Progressive multifocal leukoencephalopathy in a patient with multiple myeloma. Clinical Lymphoma, Myeloma and Leukemia. Conference: 17th International Myeloma Workshop. United States. 19 (10 Supplement) (pp e241)

  16. Woodson S, Manly C, Kwok M, Smith J (2019) Progressive multifocal leukoencephalopathy in a patient with relapsed multiple myeloma: a case report and literature review. Neurology 92(15 Supplement):P1.2–P029

    Google Scholar 

  17. Knight K, Chien S, Koutsavlis I, Campbell V (2020) Progressive multifocal leukoencephalopathy following five lines of therapy and three autologous bone marrow transplants for multiple myeloma. BMJ Case Rep 13(3):e233552

    PubMed  Google Scholar 

  18. Steinhardt MJ, Wiercinska E, Pham M, Grigoleit GU, Mazzoni A, Da-Via M, Zhou X, Meckel K, Nickel K, Duell J, Krummenast FC, Kraus S, Hopkinson C, Weissbrich B, Müllges W, Stoll G, Kortüm KM, Einsele H, Bonig H, Rasche L (2020) Progressive multifocal leukoencephalopathy in a patient post allo-HCT successfully treated with JC virus specific donor lymphocytes. J Transl Med 18(1):177 Table 2 is a summary of the characteristics and outcome of the patients including references

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Yeung J, van Hal S, Ho PJ (2019) Prolonged immunosuppression in relapsed, refractory multiple myeloma leading to cerebral toxoplasmosis and progressive multifocal leukoencephalopathy. Clin Lymphoma Myeloma Leuk 19(12):e625–e628

    PubMed  Google Scholar 

  20. Anderson S, Kiernan M, Ho PJ (2019) Lenalidomide-related progressive multifocal leukoencephalopathy: a case report and review of drug-related cases in multiple myeloma. Clin Lymphoma Myeloma Leuk 19(4):e169–e171

    PubMed  Google Scholar 

  21. Willert CB, Engsig FN, Eskildsen HW, Andersen AB (2014) Ugeskrift for laeger, 176(49), V08140432

  22. Gordon H, Bandmann M, Sandbank U (1971) Multiple myeloma associated with progressive multifocal leukoencephalopathy and Pneumocystis carinii pneumonia. Isr J Med Sci 7(4):581–588

    CAS  PubMed  Google Scholar 

  23. Navarro V, Rapado A, Capote L, Ruíz F, De la Barreda P (1973) Leucoencefalopatá multifocal progresiva en un mieloma [Progressive multifocal leukoencephalopathy in a case of myeloma]. Rev Clin Esp 131(4):319–326

    CAS  PubMed  Google Scholar 

  24. DelDuca V Jr, Morningstar WA (1967) Multiple myeloma associated with progressive multifocal leukoencephalopathy. JAMA 199(9):671–673

    PubMed  Google Scholar 

  25. Berger JR, Miller CS, Mootoor Y, Avdiushko SA, Kryscio RJ, Zhu H (2006) JC virus detection in bodily fluids: clues to transmission. Clin Infect Dis 43(1):e9–e12

    PubMed  Google Scholar 

  26. Houff SA, Major EO, Katz DA, Kufta CV, Sever JL, Pittaluga S, Roberts JR, Gitt J, Saini N, Lux W (1988) Involvement of JC virus-infected mononuclear cells from the bone marrow and spleen in the pathogenesis of progressive multifocal leukoencephalopathy. N Engl J Med 318(5):301–305

    CAS  PubMed  Google Scholar 

  27. Major EO (2010) Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med 61:35–47

    CAS  PubMed  Google Scholar 

  28. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, Anderson DR (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83(2):435–445

    CAS  PubMed  Google Scholar 

  29. Ferenczy MW, Marshall LJ, Nelson CD, Atwood WJ, Nath A, Khalili K, Major EO (2012) Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev 25(3):471–506

    CAS  PubMed  PubMed Central  Google Scholar 

  30. Hatchwell E (2015) Is there a (host) genetic predisposition to progressive multifocal leukoencephalopathy? Front Immunol 6:216

    PubMed  PubMed Central  Google Scholar 

  31. Pavlovic D, Patel MA, Patera AC, Peterson I, Progressive Multifocal Leukoencephalopathy Consortium (2018) T cell deficiencies as a common risk factor for drug associated progressive multifocal leukoencephalopathy. Immunobiology 223(6–7):508–517

    CAS  PubMed  Google Scholar 

  32. Tete SM, Bijl M, Sahota SS, Bos NA (2014) Immune defects in the risk of infection and response to vaccination in monoclonal gammopathy of undetermined significance and multiple myeloma. Front Immunol 5:257

    PubMed  PubMed Central  Google Scholar 

  33. Witzens-Harig M, Hose D, Jünger S, Pfirschke C, Khandelwal N, Umansky L, Seckinger A, Conrad H, Brackertz B, Rème T, Gueckel B, Meißner T, Hundemer M, Ho AD, Rossi JF, Neben K, Bernhard H, Goldschmidt H, Klein B, Beckhove P (2013) Tumor cells in multiple myeloma patients inhibit myeloma-reactive T cells through carcinoembryonic antigen-related cell adhesion molecule-6. Blood 121(22):4493–4503

    CAS  PubMed  Google Scholar 

  34. Zelle-Rieser C, Thangavadivel S, Biedermann R, Brunner A, Stoitzner P, Willenbacher E, Greil R, Jöhrer K (2016) T cells in multiple myeloma display features of exhaustion and senescence at the tumor site. J Hematol Oncol 9(1):116

    PubMed  PubMed Central  Google Scholar 

  35. Kawano Y, Moschetta M, Manier S, Glavey S, Görgün GT, Roccaro AM, Anderson KC, Ghobrial IM (2015) Targeting the bone marrow microenvironment in multiple myeloma. Immunol Rev 263(1):160–172

    PubMed  Google Scholar 

  36. D’Arena G, Rossi G, Laurenti L, Statuto T, D’Auria F, Valvano L, Simeon V, Giudice A, Innocenti I, De Feo V, Filosa R, Musto P (2016) Circulating regulatory T-cells in monoclonal gammopathies of uncertain significance and multiple myeloma: in search of a role. J Immunol Res 2016:9271469

    PubMed  PubMed Central  Google Scholar 

  37. Derman BA, Zha Y, Zimmerman TM, Malloy R, Jakubowiak A, Bishop MR, MD, & Kline, J. (2020) Regulatory T-cell depletion in the setting of autologous stem cell transplantation for multiple myeloma: pilot study. J Iimmunotherapy Cancer 8(1):e000286

    Google Scholar 

  38. Zhu YX, Kortuem KM, Stewart AK (2013) Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk Lymphoma 54(4):683–687

    CAS  PubMed  Google Scholar 

  39. Krejcik J, Casneuf T, Nijhof IS, Verbist B, Bald J, Plesner T, Syed K, Liu K, van de Donk NW, Weiss BM, Ahmadi T, Lokhorst HM, Mutis T, Sasser AK (2016) Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood 128(3):384–394

    CAS  PubMed  PubMed Central  Google Scholar 

  40. Ying L, YinHui T, Yunliang Z, Sun H (2017) Lenalidomide and the risk of serious infection in patients with multiple myeloma: a systematic review and meta-analysis. Oncotarget 8(28):46593–46600

    PubMed  PubMed Central  Google Scholar 

  41. Colin O, Favrelière S, Quillet A, Neau JP, Houeto JL, Lafay-Chebassier C, Pérault-Pochat MC, French Pharmacovigilance Network (2017) Drug-induced progressive multifocal leukoencephalopathy: a case/noncase study in the French pharmacovigilance database. Fundam Clin Pharmacol 31(2):237–244

    CAS  PubMed  Google Scholar 

  42. Seong D, Bruner JM, Lee KH, Mirza N, Kwon BD, Lee JH, Lee YY, Ro J, Talpaz M, Champlin R, Deisseroth AB (1996) Progressive multifocal leukoencephalopathy after autologous bone marrow transplantation in a patient with chronic myelogenous leukemia. Clin Infect Dis 23(2):402–403

    CAS  PubMed  Google Scholar 

  43. Fukuoka K, Kaneko T, Akiyama M (2011) Progressive multifocal leukoencephalopathy in a 16-year-old patient with pancytopenia after autologous bone marrow transplantation for relapsed Hodgkin lymphoma. Pediatr Blood Cancer 56(3):507–508

    PubMed  Google Scholar 

  44. Re D, Bamborschke S, Feiden W, Schröder R, Lehrke R, Diehl V, Tesch H (1999) Progressive multifocal leukoencephalopathy after autologous bone marrow transplantation and alpha-interferon immunotherapy. Bone Marrow Transplant 23(3):295–298

    CAS  PubMed  Google Scholar 

  45. Power C, Gladden JG, Halliday W, Del Bigio MR, Nath A, Ni W, Major EO, Blanchard J, Mowat M (2000) AIDS- and non-AIDS-related PML association with distinct p53 polymorphism. Neurology 54(3):743–746

    CAS  PubMed  Google Scholar 

  46. Teoh PJ, Chng WJ (2014) p53 abnormalities and potential therapeutic targeting in multiple myeloma. Biomed Res Int 2014:717919

    CAS  PubMed  PubMed Central  Google Scholar 

  47. Eis PS, Bruno CD, Richmond TA, Koralnik IJ, Hanson BA, Major EO, Chow CR, Hendel-Chavez H, Stankoff B, Gasnault J, Taoufik Y, Hatchwell E (2020) Germline genetic risk variants for progressive multifocal leukoencephalopathy. Front Neurol 11:186

    PubMed  PubMed Central  Google Scholar 

  48. Neil EC, DeAngelis LM (2017) Progressive multifocal leukoencephalopathy and hematologic malignancies: a single cancer center retrospective review. Blood Adv 1(23):2041–2045

    PubMed  PubMed Central  Google Scholar 

  49. Raajasekar AKA, Ayyapan S, Khan H, Mantzaris I, Janakiramet M (2016) Progressive multifocal leukoencephalopathy associated with hematopoietic stem cell transplant (HSCT) has better prognosis than PML associated with monoclonal antibodies or chemotherapy in hematological malignancies: analysis of a case series. Biol Blood Marrow Transplant 22:S153–S154

    Google Scholar 

  50. Dong-Si T, Richman S, Wattjes MP, Wenten M, Gheuens S, Philip J, Datta S, McIninch J, Bozic C, Bloomgren G, Richert N (2014) Outcome and survival of asymptomatic PML in natalizumab-treated MS patients. Ann Clini Transl Neurol 1(10):755–764

    Google Scholar 

  51. De Luca A, Ammassari A, Pezzotti P, Cinque P, Gasnault J, Berenguer J, Di Giambenedetto S, Cingolani A, Taoufik Y, Miralles P, Marra CM, Antinori A, Gesida 9/99, IRINA, ACTG 363 Study Groups (2008) Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis. AIDS (London, England) 22(14):1759–1767

    Google Scholar 

  52. Marzocchetti A, Tompkins T, Clifford DB, Gandhi RT, Kesari S, Berger JR, Simpson DM, Prosperi M, De Luca A, Koralnik IJ (2009) Determinants of survival in progressive multifocal leukoencephalopathy. Neurology 73(19):1551–1558

    CAS  PubMed  PubMed Central  Google Scholar 

  53. Elphick GF, Querbes W, Jordan JA, Gee GV, Eash S, Manley K, Dugan A, Stanifer M, Bhatnagar A, Kroeze WK, Roth BL, Atwood WJ (2004) The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science (New York, N.Y.) 306(5700):1380–1383

    CAS  Google Scholar 

  54. Brickelmaier M, Lugovskoy A, Kartikeyan R, Reviriego-Mendoza MM, Allaire N, Simon K, Frisque RJ, Gorelik L (2009) Identification and characterization of mefloquine efficacy against JC virus in vitro. Antimicrob Agents Chemother 53(5):1840–1849

    CAS  PubMed  PubMed Central  Google Scholar 

  55. Yoshida H, Masaie H, Hino A, Ishikawa J (2017) A new therapeutic option for progressive multifocal leukoencephalopathy after allogeneic hematopoietic cell transplantation. J Clin Infect Dis Pract 2:116

    Google Scholar 

  56. Cortese I, Muranski P, Enose-Akahata Y, Ha SK, Smith B, Monaco M, Ryschkewitsch C, Major EO, Ohayon J, Schindler MK, Beck E, Reoma LB, Jacobson S, Reich DS, Nath A (2019) Pembrolizumab treatment for progressive multifocal leukoencephalopathy. N Engl J Med 380(17):1597–1605

    CAS  PubMed  Google Scholar 

  57. Gascó AF, Vericat JM, Albir MJ, Robles GAA, Puigcerver CF, López OB, Megía MJF, Miralles FCP, Andrés JLP, Estruch BC (2017) CP-070 interleukin-2 treatment of two patients with multifocal progressive leukoencephalopathy associated with HIV infection. Eur J Hosp Pharm 24:A31

    Google Scholar 

  58. Dubey D, Zhang Y, Graves D, DeSena AD, Frohman E, Greenberg B (2016) Use of interleukin-2 for management of natalizumab-associated progressive multifocal leukoencephalopathy: case report and review of literature. Ther Adv Neurol Disord 9(3):211–215

    CAS  PubMed  Google Scholar 

  59. Muftuoglu M, Olson A, Marin D, Ahmed S, Mulanovich V, Tummala S, Chi TL, Ferrajoli A, Kaur I, Li L, Champlin R, Shpall EJ, Rezvani K (2018) Allogeneic BK virus-specific T cells for progressive multifocal leukoencephalopathy. N Engl J Med 379(15):1443–1451

    CAS  PubMed  PubMed Central  Google Scholar 

  60. Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C (2012) Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 366(20):1870–1880

    CAS  PubMed  Google Scholar 

  61. Berger JR, Fox RJ (2016) Reassessing the risk of natalizumab-associated PML. J Neuro-Oncol 22(4):533–535

    CAS  Google Scholar 

  62. Plavina T, Subramanyam M, Bloomgren G, Richman S, Pace A, Lee S, Schlain B, Campagnolo D, Belachew S, Ticho B (2014) Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 76(6):802–812

    CAS  PubMed  Google Scholar 

  63. Berger JR, Levy RM, Flomenhoft D, Dobbs M (1998) Predictive factors for prolonged survival in acquired immunodeficiency syndrome-associated progressive multifocal leukoencephalopathy. Ann Neurol 44(3):341–349

    CAS  PubMed  Google Scholar 

  64. Dong-Si T, Gheuens S, Gangadharan A, Wenten M, Philip J, McIninch J, Datta S, Richert N, Bozic C, Bloomgren G, Richman S, Weber T, Clifford DB (2015) Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy. J Neuro-Oncol 21(6):637–644

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. NHS Fife, Haematology, Victoria Hospital, Kirkcaldy, KY2 5AH, UK

    Ioannis Koutsavlis

Authors
  1. Ioannis Koutsavlis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ioannis Koutsavlis.

Ethics declarations

Conflict of interest

The author declares that he has no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Code availability

Not applicable.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Koutsavlis, I. Progressive multifocal leukoencephalopathy in multiple myeloma. A literature review and lessons to learn. Ann Hematol 100, 1–10 (2021). https://doi.org/10.1007/s00277-020-04294-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-020-04294-x

Keywords

Search

Navigation